Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angiotech Pharmaceuticals has reported positive clinical data from its 960 patient clinical trial comparing its 5-Fluorouracil-coated Central Venous Catheter with a chlorhexidine or silver sulfadiazine coated Central Venous Catheter.
Subscribe to our email newsletter
Based on the clinical trial data, the investigators concluded that Angiotech’s 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) met the primary endpoint of the study: non-inferior in its ability to prevent bacterial colonization of the catheter tip when compared to catheters coated with chlorhexidine or silver sulfadiazine (CH-SS). The rate of colonization of the 5-FU CVC was 2.9% (n=12), compared to 5.3% (n=21) in the CH-SS coated catheters (relative reduction in colonization with 5-FU coating of 46%, p=0.055).
There were no statistically significant differences in the rate of adverse events related to the study devices (2.5% for 5-FU versus 3.1% for CH-SS), or in the rates of catheter-related bloodstream infections (CRBSI), (0% for 5-FU versus 2.8% for CH-SS). In addition to meeting the non-inferiority endpoint, these data show a trend toward superiority for the 5-FU coated catheter over the market leading device, both in frequency and nature of colonizations and infections.